Advanced

Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome.

Theander, Elke LU ; Horrobin, David F; Jacobsson, Lennart LU and Manthorpe, Rolf LU (2002) In Scandinavian Journal of Rheumatology 31(2). p.72-79
Abstract
Objective: To evaluate the eYcacy of the essential omega-6 fatty acid Gammalinolenic acid (GLA) on fatigue associated with primary

Sjo¨ gren’s syndrome.

Methods: Ninety patients with primary Sjo¨ gren’s syndrome (with or without signs of autoimmunity) entered a 6-month double blind

placebo-controlled randomised trial with high dose GLA (extracted from Evening Primrose Oil ) or corn oil. The primary outcome

parameter was fatigue; secondary endpoints were eye dryness, mouth dryness, muscle and joint pain.

Results: No statistically signiŽ cant improvement was found in fatigue assessed by Visual Analogue Scale (VAS) or in the time needed for

sleeping/resting during a 24-hour period. No... (More)
Objective: To evaluate the eYcacy of the essential omega-6 fatty acid Gammalinolenic acid (GLA) on fatigue associated with primary

Sjo¨ gren’s syndrome.

Methods: Ninety patients with primary Sjo¨ gren’s syndrome (with or without signs of autoimmunity) entered a 6-month double blind

placebo-controlled randomised trial with high dose GLA (extracted from Evening Primrose Oil ) or corn oil. The primary outcome

parameter was fatigue; secondary endpoints were eye dryness, mouth dryness, muscle and joint pain.

Results: No statistically signiŽ cant improvement was found in fatigue assessed by Visual Analogue Scale (VAS) or in the time needed for

sleeping/resting during a 24-hour period. No diVerences were found between the treatment and placebo group. The same applies to the

secondary endpoints: no diVerences in VAS for eye and mouth dryness or pain, no signiŽ cant changes in Schirmer-1-test, van Bijsterveld

score, unstimulated whole sialometry (UWS), or use of artiŽ cial tears or analgesics. Only mild side eVects were observed.

Conclusion: According to our study results GLA (Evening Primrose oil ) treatment for fatigue in primary Sjo¨gren’s syndrome is ineVective. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Non-U.S. Gov't, Treatment Outcome, gamma-Linolenic Acid: administration & dosage, Fatigue: etiology, Fatty Acids, Aged, Dermatologic Agents, Double-Blind Method, Fatigue: drug therapy, gamma-Linolenic Acid: adverse effects, Essential, Female, Human, Male, Middle Age, Patient Compliance, Sjogren's Syndrome: complications, Sjogren's Syndrome: drug therapy, Support
in
Scandinavian Journal of Rheumatology
volume
31
issue
2
pages
72 - 79
publisher
Taylor & Francis
external identifiers
  • wos:000175867000004
  • pmid:12109650
  • scopus:0036094653
ISSN
1502-7732
DOI
10.1080/03009740252937577
language
English
LU publication?
yes
id
7bf983e8-d155-44cf-bcb1-d1a1434da82d (old id 115120)
date added to LUP
2007-07-30 11:19:32
date last changed
2017-10-08 03:27:26
@article{7bf983e8-d155-44cf-bcb1-d1a1434da82d,
  abstract     = {Objective: To evaluate the eYcacy of the essential omega-6 fatty acid Gammalinolenic acid (GLA) on fatigue associated with primary<br/><br>
Sjo¨ gren’s syndrome.<br/><br>
Methods: Ninety patients with primary Sjo¨ gren’s syndrome (with or without signs of autoimmunity) entered a 6-month double blind<br/><br>
placebo-controlled randomised trial with high dose GLA (extracted from Evening Primrose Oil ) or corn oil. The primary outcome<br/><br>
parameter was fatigue; secondary endpoints were eye dryness, mouth dryness, muscle and joint pain.<br/><br>
Results: No statistically signiŽ cant improvement was found in fatigue assessed by Visual Analogue Scale (VAS) or in the time needed for<br/><br>
sleeping/resting during a 24-hour period. No diVerences were found between the treatment and placebo group. The same applies to the<br/><br>
secondary endpoints: no diVerences in VAS for eye and mouth dryness or pain, no signiŽ cant changes in Schirmer-1-test, van Bijsterveld<br/><br>
score, unstimulated whole sialometry (UWS), or use of artiŽ cial tears or analgesics. Only mild side eVects were observed.<br/><br>
Conclusion: According to our study results GLA (Evening Primrose oil ) treatment for fatigue in primary Sjo¨gren’s syndrome is ineVective.},
  author       = {Theander, Elke and Horrobin, David F and Jacobsson, Lennart and Manthorpe, Rolf},
  issn         = {1502-7732},
  keyword      = {Non-U.S. Gov't,Treatment Outcome,gamma-Linolenic Acid: administration & dosage,Fatigue: etiology,Fatty Acids,Aged,Dermatologic Agents,Double-Blind Method,Fatigue: drug therapy,gamma-Linolenic Acid: adverse effects,Essential,Female,Human,Male,Middle Age,Patient Compliance,Sjogren's Syndrome: complications,Sjogren's Syndrome: drug therapy,Support},
  language     = {eng},
  number       = {2},
  pages        = {72--79},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Rheumatology},
  title        = {Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome.},
  url          = {http://dx.doi.org/10.1080/03009740252937577},
  volume       = {31},
  year         = {2002},
}